IBTROZI Approval Tests FDA's Tolerance for China-Only Trial Data

Nuvation Bio's IBTROZI (taletrectinib) cleared FDA review on June 11, 2025, for ROS1-positive non-small cell lung cancer -- but the evidentiary foundation rests partly on a trial conducted exclusively in China, placing the approval at the center of an ongoing regulatory debate over foreign clinical data acceptance and the adequacy of manufacturing site oversight under strained FDA-China inspection relations.

The agency based its approval on data from 270 patients enrolled across two trials: TRUST-I (NCT04395677), conducted exclusively in China, and TRUST-II (NCT04919811), a global study spanning North America, Europe, and Asia. The efficacy analysis covered two distinct subgroups -- TKI-naive patients and those who had received one prior ROS1-targeted therapy. In the TKI-naive TRUST-I cohort of 103 patients, 100% were Asian; the TRUST-II naive cohort of 54 patients showed broader representation, including 22% White and 1.9% Black or African American participants. Safety was evaluated across 352 patients, of whom 76% were Asian and 15% White.

For regulatory affairs teams, the TRUST-I dataset presents a direct ICH E5 applicability question: whether pharmacogenomic and population-specific response data generated in a homogeneous Asian cohort can be extrapolated to support labeling for a broader global population without bridging studies. The racial composition of the safety population -- 76% Asian -- compounds this concern when assessing whether adverse event profiles are generalizable across the patient populations that prescribers in the US and Europe will actually treat.

IBTROZI is administered as a 200 mg capsule at 600 mg once daily on an empty stomach, with no food intake permitted at least two hours before or after dosing. The approved indication covers adult patients with locally advanced or metastatic NSCLC harboring an abnormal ROS1 gene. QA and manufacturing teams should note that the site inspection landscape for China-based manufacturing and clinical operations remains a live compliance variable as FDA works through its post-pandemic inspection backlog.

Source: FDA Drug Trials Snapshots -- IBTROZI, published April 28, 2026. Approval date confirmed as June 11, 2025.